Marengo Asia Hospitals was advised by Avendus Capital on this transaction.

Established in 2021, Marengo Asia Hospitals has grown through a focused buy-and-build strategy, acquiring established regional hospitals and strengthening their clinical and operating capabilities, the firm said in a statement. The company operates five hospitals in India and has a partnership in Saudi Arabia, with about 2,000 beds, serving more than 900,000 patients annually. It has a presence across Gujarat and a growing footprint in Delhi National Capital Region (NCR), with advanced capabilities across high-acuity specialties including cardiology, oncology, neurology, gastroenterology, orthopaedics, and renal care and transplants.

India’s healthcare needs are rising rapidly. Non-communicable diseases (NCDs) such as cardiovascular disease, cancer and diabetes account for 66 per cent of deaths nationally, driving demand for specialist care. Yet India has only 1.5 hospital beds per 1,000 people, around 55 per cent below the global average. Marengo Asia Hospitals is helping address this gap by expanding access to high-quality, specialised healthcare.

Aberdeen Investments
on Friday launched the abrdn SICAV I – Emerging Markets Equity Enhanced Index Fund, expanding its Enhanced Index range and complementing the existing World, American and European Equity Enhanced Index strategies within its Luxembourg-domiciled SICAV vehicle launched in January 2026.

The fund aims to deliver long-term capital growth by investing in emerging market equities and targeting returns in excess of the MSCI Emerging Markets 10/40 Index before charges over rolling 5-year periods. The ongoing charges figure (OCF) is expected to be about 0.66 per cent.

The fund will be available for distribution in Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Singapore, Sweden, Switzerland and the UK.

Enhanced index portfolios blend active and passive approaches, aiming to modestly outperform benchmarks with diversified exposure to core equity markets, through a quantitative, data-led strategy.

The launch comes amid renewed investor interest in emerging market equities, the firm said in a statement. As at 30 June 2026, the MSCI Emerging Markets Index had returned 22.6 per cent year-to-date, outperforming both the MSCI ACWI Index (10.4 per cent) and the S&P 500 Index (9.6 per cent). Investor demand has been supported by concerns around US market concentration and the dominance of the technology sector, alongside attractive valuations, resilient economic fundamentals and sustained capital investment trends across emerging economies.